Key facts
- This page summarizes Margaret M. FitzPatrick's Form 4 filing for Vistagen Therapeutics, Inc. (VTGN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 11 Sep 2025, 18:15.
Margaret M. FitzPatrick - 09 Sep 2025 Form 4 Insider Report for Vistagen Therapeutics, Inc. (VTGN)
- Reporting relationship
- Director
- Issuer ticker
- VTGN
- Reported as of
- 09 Sep 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Sep 2025, 18:15:13 UTC
- Prior SEC filing
- 29 May 2025
- Next SEC filing
- 23 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Cynthia Anderson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Margaret M. FitzPatrick filed Form 4 for Vistagen Therapeutics, Inc. (VTGN) on 11 Sep 2025.
Change
- Previous filing in this sequence was filed on 29 May 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001873879
Primary reporting owner
FitzPatrick Margaret M
- Relationship
- Director
- Address
- C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE, SOUTH SAN FRANCISCO
- Signature
- /s/ Cynthia Anderson, Attorney-in-Fact
- Signature date
- 11 Sep 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VTGN
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +17,600
- Change %
- Price
- $0.000000
- Shares after
- 17,600
- Date
- 09 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,600
- Exercise price
- $3.61
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, which vest in twelve equal monthly installments, beginning on the date of the grant.